Search

313 Result(s)
Sort by

Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Veganism

Veganism

Hear an expert’s opinion on the proposed link between a vegan diet and cancer recurrence rates.
Social Support

Social Support

People living with cancer share their perspectives on the importance of social support.
Nutrition

Nutrition

People with cancer discuss the benefits she experienced through making dietary changes whilst undergoing cancer treatment.
Advice to Fellow Patients

Advice to Fellow Patients

People living with cancer share their advice for fellow patients, from checking information sources to living in the present moment.
TCO patient podcasts

TCO patient podcasts

From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
Physical Wellbeing

Physical Wellbeing

Resources and videos related to physical wellbeing whilst living with cancer.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
IPF why wait?

IPF why wait?

IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF